Reading CCCC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CCCC free→Reading CCCC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CCCC free→QuarterlyIQ Insights · CCCC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Principal Accounting Officer On May 12, 2026, C4 Therapeutics, Inc. (the “Company”) determined that Mark Mossler will no longer serve as the Company’s Chief Accounting Officer, effective May 15, 2026. Mr. Mossler’s departure from the Company is not due to any disagreement with the Company or the Company’s Board of Directors on any matt…
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. On April 8, 2026 , C4 Therapeutics, Inc. (“ C4T ”) entered into a Research Collaboration and License Agreement ( the “ License Agreement ”) with F. Hoffmann-La Roche Ltd. (“ Roche Basel ”) and Hoffmann-La Roche Inc. (“ Roche US ”, and together with Roche Basel, “ Roche ”) to collaborate on the discovery, development and commercialization of degrader-antibody conjugates (“ DACs ”), an emerging modality designed to selectively target and neutralize di…
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 , as amended (the “ Securities Act ”), or the Exchange Act, except as expressly set forth by specific reference in…
Entry into a Material Definitive Agreement. On October 16, 2025, C4 Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C. (collectively, the “Underwriters”), related to an underwritten offering (the “Offering”) of (i) 21,895,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) in lieu of Common Stock to certain inve…
Other Events. On October 16, 2025, C4 Therapeutics, Inc. (the “ Company ”) posted a presentation with data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma. The presentation has been published to the “Events & Presentations” page of the investor relations section of the Company’s website and is for use in meetings with investors, analysts and others. The presentation is filed as Exhibit 99.1 to this Curr…
of this Current Report on Form 8-K contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding the Company’s ability to develop potential therapies for patients; the design and potential efficacy of the Company’s therapeutic approaches; the predictive capability of the Company’s TORPEDO® platform in the…
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 , as amended (the “ Securities Act ”), or the Exchange Act, except as expressly set forth by specific reference in…
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Director On April 10, 2025, Bruce Downey notified the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”) of his intention to retire from the Board and not to stand for reelection at the 2025 Annual Meeting of Stockholders. Mr. Downey’s decision not to stand for reelection was not due to any disagreements with…
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'full' to 'fair'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.